GlaxoSmithKline (GSK) is a British multinational pharmaceutical company headquartered in London, with operations in over 100 countries. The company has maintained a strategic interest in neuroscience, with particular focus on neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
| Attribute |
Value |
| Ticker |
NYSE: GSK, LSE: GSK |
| Founded |
2000 (merger of Glaxo Wellcome and SmithKline Beecham) |
| Headquarters |
London, United Kingdom |
| CEO |
Emma Walmsley |
| Market Cap |
~$85 billion USD (2024) |
| R&D Budget |
~£5 billion annually |
| Employees |
~70,000 worldwide |
GSK operates as one of the world's largest pharmaceutical companies with three main business divisions:
- Vaccines: Leading vaccine developer and manufacturer
- Specialty Medicines: Oncology, immunology, and rare diseases
- General Medicines: Broad portfolio of established medicines
Neuroscience research falls primarily within the Specialty Medicines division.
¶ Research and Development
GSK maintains significant R&D operations:
- Global R&D centers in UK, US, and Belgium
- Focus on human genetics and immunology
- Emphasis on targeted therapies and biomarkers
| Program |
Target |
Mechanism |
Stage |
| Tau programs |
Tau protein |
Various approaches |
Discovery |
| OT-805 |
Tau |
Antibody |
Preclinical |
| AL101 collaboration |
Progranulin |
Antibody |
Phase 2 (with Alector) |
| Neuroinflammation |
TREM2, IL-34/CSF-1R |
Immunomodulation |
Research |
| Gamma-secretase |
APP processing |
Modulator |
Previous trials |
| Program |
Target |
Mechanism |
Stage |
| LRRK2 programs |
LRRK2 kinase |
Kinase inhibitors |
Discovery |
| GBA programs |
Glucocerebrosidase |
Chaperones |
Preclinical (with Gain) |
| Alpha-synuclein |
α-Syn |
Various approaches |
Research |
| Mitochondrial targets |
Mitochondrial dysfunction |
Neuroprotection |
Research |
GSK maintains research programs in:
- Multiple CNS disorders
- Neuropsychiatric conditions
- Pain and sensory disorders
- Rare neurological diseases
- Genomics and genetics: Target discovery through human genetics
- Immunology expertise: Neuroinflammation modulation approaches
- Gene therapy: Exploring gene therapy for neurological disorders
- Small molecule platform: Kinase inhibitors for CNS targets
- Human Genetics: Leveraging UK Biobank and genetic databases
- Immunology: Applying immunological expertise to neuroinflammation
- RNAi/siRNA: RNA interference technologies
- AAV vectors: Adeno-associated virus for gene delivery
GSK employs multiple modalities:
- Small molecule inhibitors
- Monoclonal antibodies
- Gene therapy vectors
- RNA-based therapeutics
GSK's Alzheimer's research includes:
- Tau-targeting therapeutics: Including OT-805 in partnership
- Amyloid research: Through partnerships with biotech companies
- Neuroinflammation modulation: TREM2, IL-34/CSF-1R pathways
- Synaptic plasticity: Memory restoration approaches
- Genetic risk factors: APOE, TREM2, and other GWAS hits
Parkinson's programs focus on:
- LRRK2 inhibitor research: GSK'257 and related compounds
- Alpha-synuclein targeting: Multiple modalities
- Neuroprotective strategies: Disease modification
- Mitochondrial dysfunction pathways: Targeting energy metabolism
- GBA-related PD: Collaborations with Gain Therapeutics
- Alector: AL101 (progranulin antibody) — 50-50 US profit share, tiered royalties ex-US
- Gain Therapeutics: GCase modulators for PD
- Tau-targeting biotech: Various collaborations on tau programs
- Gene therapy companies: AAV delivery partnerships
- Oxford University: Neuroscience research collaboration
- Cambridge University: Neurodegeneration research
- UK Dementia Research Institute: Dementia research initiatives
- Parkinson's Progression Markers Initiative (PPMI): Disease progression research
- CRANBERRY Project: EU-funded neurodegeneration biomarker research
- Michael J. Fox Foundation: LRRK2 genetics collaboration
GSK has conducted multiple AD trials:
- Gamma-secretase modulator trials (completed)
- Multiple Phase 1/2 studies
- Current Phase 2 trials with Alector
- LRRK2 inhibitor studies
- Neuroprotective agent trials
- Combination therapy trials
- Emma Walmsley (CEO) — Leading company's strategic direction
- Dr. Tony Wood (Chief Scientific Officer)
- Dr. John Kemp (Former Head of Neuroscience Research)
| Metric |
Value |
| Market Cap |
~$85 billion |
| Annual Revenue |
~£30 billion |
| R&D Investment |
~£5 billion/year |
| Neuroscience (est.) |
5-8% of R&D |
GSK's neuroscience programs address key mechanisms in neurodegenerative diseases: